Akebia Therapeutics

top of page

Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs

He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement inhibitor from Q32 Bio. Coverage brought to you by

Company News

Apr 14

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs

Follow BiotechTV

Sponsors

Sponsor Spotlight